The therapeutic effect of intralesional interferon in classical Kaposi's sarcoma

A. Trattner*, Z. Reizis, M. David, A. Ingber, J. Hagler, M. Sandbank

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Interferon alpha-2a, which has antineoplastic, antiviral, immunomodulatory, and antiangiogenic effects, was evaluated in a prospective study, treating 10 lesions of patients with classical Kaposi's sarcoma. Ten patients received injections of interferon alpha-2a intralesionally in a dose of 3 million units three times weekly for 4 weeks, and in a variable dose for 4 more weeks. Two of the patients had a complete response, and in one of these, distant lesions also responded. Seven had a partial response, and one did not respond. The treatment was generally well tolerated. The results of our study support the use of interferon in the therapy of classical Kaposi's sarcoma, although it would appear that to achieve maximum efficacy, a longer period of treatment is needed.

Original languageEnglish
Pages (from-to)590-593
Number of pages4
JournalBritish Journal of Dermatology
Issue number5
StatePublished - 1993
Externally publishedYes


Dive into the research topics of 'The therapeutic effect of intralesional interferon in classical Kaposi's sarcoma'. Together they form a unique fingerprint.

Cite this